AXIM Biotechnologies Publishes Study Highlighting Neutralizing Antibody Levels of Poor Vaccine Responders with a Third COVID-19 Vaccine Dose

Rhea-AI Summary

SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. announced a publication with Arizona State University titled, "Third COVID-19 Vaccine Dose Boosts Neutralizing Antibodies in Poor Responders" in Communications Medicine. The study revealed that 25% of vaccine recipients did not achieve adequate neutralizing antibodies after two doses, but a third dose significantly increased these levels within two weeks. AXIM's rapid test, co-developed with ASU, quantitatively measures neutralizing antibodies, underscoring its potential role in personalized medicine.

Positive

• Collaboration with Arizona State University on a significant clinical study.
• Publication in a high-profile journal, Communications Medicine.
• Rapid test effectively identifies vaccine poor responders needing a third dose.
• Potential for AXIM's test to be used by major vaccine manufacturers.

Negative

• Only 25% of two-dose vaccine recipients achieved adequate neutralizing antibodies, indicating a significant public health concern.
• The reliance on a third dose for adequate protection could impact public perception of the initial vaccine efficacy.

SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company, announced today their publication in collaboration with researchers at Arizona State University (ASU) entitled, “Third COVID-19 Vaccine Dose Boosts Neutralizing Antibodies in Poor Responders” in Communications Medicine, part of the Nature family of journals.

AXIM and ASU performed a clinical study using their co-developed rapid test and discovered that even after two doses, COVID-19 RNA vaccines were unable to elicit high levels of neutralizing antibodies in 25% of vaccine recipients. However, a third vaccine dose rescued these “vaccine poor responders”, boosting their neutralizing antibodies to levels that are highly protective within two weeks of receiving a third dose. The rapid 10-minute test quantitatively measures levels of neutralizing antibodies in a finger stick drop of blood.

Dr. Douglas Lake, Associate Professor and researcher at ASU, and Dr. Sergei Svarovsky, Chief Scientific Officer at AXIM, co-inventors of the test, indicated that they were pleased by the acceptance by Communications Medicine because it is in the family of high profile and widely read Nature journals.

Dr. Svarovsky stated, “Communications Medicine recognized the importance of our work in showcasing that as many as 25% of two-dose vaccine recipients are unaware their vaccines, primary and booster, did not generate an adequate amount of neutralizing antibodies. This work underscores the importance of a third dose and that vaccine poor responders aren’t permanently poor responders – they need another dose to be adequately protected.”

John Huemoeller, CEO of AXIM Biotech added, “This study made me curious of how many people received two doses of vaccine and decided not to get a third dose. Our study clearly demonstrated that two doses of vaccine may not protect everyone. There are many people that currently need a third dose but won’t know it unless they use our rapid test. Our test incorporates the concept of individualized medicine since not everyone responds uniformly to the vaccines. We have now developed and validated an Omicron-based rapid neutralizing antibody test that vaccine companies such as Moderna and Pfizer may want to employ to quickly evaluate efficacy of their future Omicron booster in recipients.”

About AXIM® Biotechnologies
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on improving the landscape for diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests. Additionally, it owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells, as well as for oncological indications. For more information, please visit www.AXIMBiotech.com.

Forward-Looking Statements
The statements made by AXIM Biotechnologies Inc., in this press release, may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Axim’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Axim Biotechnologies, Inc. Actual results could differ materially from those projected due to there being no assurance that our diagnostic candidate will be successfully shown to detect SARS-CoV-2 neutralizing antibodies, that the diagnostic candidate will be approved for use by the U.S. FDA or any equivalent foreign regulatory agency, that the diagnostic candidate can be manufactured in large quantities or that third parties with an established presence in blood collection clinics, vaccine development, employer or individual use will enter into agreements or purchase from the Company, and even if the Company’s diagnostic candidate is successful, it may generate only limited revenue and profits for the Company, including whether any of Axim’s diagnostic products will receive clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to sell its products and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies, the fact that there has never been a commercial diagnostic test utilizing neutralizing antibodies approved for use and various other factors detailed from time to time in Axim’s SEC reports and filings, including our Annual Report on Form 10-K filed on April 15, 2021 and other reports we file with the SEC, which are available at www.sec.gov. Axim Biotechnologies, Inc., undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.

CONTACT
Public Relations
Kathryn Brown, Account Director
CMW Media
P. 858-221-8001
kathryn@cmwmedia.com

AXIM Corporate
6191 Cornerstone Ct., Ste. 114
San Diego, CA 92121, USA
P. 858-923-4422

Investor Relations
investors@aximbiotech.com
888-759-0844

 

FAQ

What does AXIM's recent study published in <em>Communications Medicine</em> reveal?

The study shows that 25% of two-dose COVID-19 vaccine recipients do not have adequate neutralizing antibodies, but a third dose can significantly boost these levels.

How does AXIM's rapid test work?

AXIM's rapid test quantitatively measures neutralizing antibodies from a finger stick drop of blood, providing results in 10 minutes.

Why is the third vaccine dose important according to AXIM's study?

The third dose is crucial as it can elevate neutralizing antibodies to protective levels in those who did not respond adequately to the initial two doses.

What new findings are associated with AXIM's vaccine study?

The study indicates that many individuals may not realize their vaccination did not provide them with sufficient immunity, emphasizing the need for personalized medicine.

What implications does AXIM's rapid test have for vaccine manufacturers?

AXIM's test could be valuable for vaccine companies like Moderna and Pfizer to assess the efficacy of future booster shots.